Optimi Health Corp. IPO: What to Know Before It Lists
Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.
Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.
Optimi Health Corp. (NASDAQ: OPTH) is expected to list on 2026-05-20, with a price range not disclosed and 2,500,000 shares offered. The setup is a small, early commercial psychedelic manufacturer with real revenue, but it is still carrying losses, a working capital deficit, and heavy regulatory dependence.
Quick Facts
Expected listing date: May 20, 2026
Exchange: NASDAQ
Proposed symbol: OPTH
Shares offered: 2.50M shares
Implied market cap: $23M
Status:
Expected
Company Overview
Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer focused on finished-dose psilocybin and MDMA capsules. The company says it operates a Health Canada Drug Establishment-licensed, GMP-compliant facility in Princeton, British Columbia, and supplies products to authorized prescribers in Australia under the TGA Authorized Prescriber Scheme. It also says it is built to scale into additional jurisdictions as regulation develops, including the U.S. if federal rescheduling occurs.
The business is still narrow in scope and geography. In the filing, Optimi disclosed only a single customer-related deferred revenue balance of C$207,759 as of December 31, 2025, tied to deposits for drug product purchase orders, and it expected commercial shipments valued at C$93,000 to that customer in January 2026. The company was incorporated on May 27, 2020, changed its name to Optimi Health Corp. on August 17, 2020, and is headquartered at 269 David Brown Way, Princeton, British Columbia.
Why They're Going Public
Optimi says it expects to use net proceeds to scale production and distribution of its products, expand into new markets, support sales growth, fund general working capital, and cover other operating expenses. Management will have broad discretion over how the proceeds are deployed.
For a company at this stage, the IPO is mainly about funding execution. The listing should give Optimi more flexibility to support commercialization, strengthen its balance sheet, and pursue market expansion as the psychedelic regulatory environment evolves.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Optimi is generating revenue, but at a very small scale. For the fiscal year ended September 30, 2025, revenue was C$426,301, up from C$389,850 in FY2024 and C$181,087 in FY2023. That works out to 9.4% year-over-year growth versus FY2024, which shows progress, but not yet a large commercial base.
Profitability remains well out of reach. The company reported a net loss and comprehensive loss of C$(3,712,031) in FY2025, improved from C$(6,035,859) in FY2024. Operating cash flow was negative C$2,627,901 in FY2025, and cash and cash equivalents were C$1,145,065 at September 30, 2025. The company also reported a working capital deficiency of C$(6,657,383), which underscores the need for fresh capital even as losses narrowed year over year.
Risk Factors
The biggest risk is regulation. Optimi’s business depends on licenses, controlled substances rules, and changing legal frameworks, and the company itself says the U.S. opportunity remains contingent on federal rescheduling. That means the addressable market can expand, but only if regulators move in the company’s favor.
The second major issue is scale. The filing shows limited commercialization, with only one customer-related deferred revenue balance disclosed and no broader customer count. Add in the C$(6,657,383) working capital deficiency, negative operating cash flow, and ongoing losses, and the IPO looks like a financing step as much as a growth milestone. Shareholders should also watch dilution and lock-up dynamics, since directors, officers, and certain shareholders are subject to 180-day lock-ups and the underwriter receives warrants.
Comparable Public Companies
Closest public comps in the psychedelic and adjacent regulated-drug space include Compass Pathways plc (CMPS), Mind Medicine (MindMed) Inc. (MNMD), Atai Life Sciences N.V. (ATAI), Cybin Inc. (CYBN), and GH Research PLC (GHRS). These companies give investors a read on how the market values clinical or regulated psychedelic exposure, though Optimi is more manufacturing- and commercialization-focused than many of the development-stage peers.
Against those names, Optimi is much smaller in revenue terms and earlier in commercial scale. The company’s FY2025 revenue of C$426,301 is modest relative to public peers with broader capital markets profiles, but its finished-dose manufacturing model gives it a different operating angle than pure research-stage psychedelic developers. The IPO will likely be judged less on current size and more on whether the company can convert regulatory access into repeatable sales growth.
Verdict
What to watch as Optimi prices is whether the market gives it credit for being one of the few commercial-stage psychedelic manufacturers with actual revenue, even if the base is still tiny. The setup favors investors who want exposure to a regulated manufacturing model rather than a pure drug-development story, but the company still needs to prove it can scale beyond a narrow customer footprint.
The key tension is straightforward: revenue is growing, losses are narrowing, and the IPO should add balance-sheet flexibility, but the business remains highly dependent on regulation, customer access, and continued financing support. If pricing comes in at a level that reflects the early-stage nature of the business, the IPO could be a watchlist name for shareholders tracking the psychedelic sector; if valuation gets ahead of the current commercial footprint, the risk-reward becomes harder to justify.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
